GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accele

GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch

Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China